AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca PLC announced that on March 4, 2025, its CEO Pascal Soriot and CFO Aradhana Sarin received awards of ordinary shares under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). These awards are part of the company’s incentive plans, with shares under the AZDBP representing deferred portions of annual bonuses and subject to a three-year holding period. The AZPSP awards are contingent on performance measures over three years, with a subsequent two-year holding period, reflecting AstraZeneca’s focus on aligning executive compensation with long-term performance goals.
More about AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.
YTD Price Performance: 16.92%
Average Trading Volume: 2,713,154
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £187.1B
For an in-depth examination of AZN stock, go to TipRanks’ Stock Analysis page.